 BOSTON, March 03, 2022 GLOBE NEWSWIRE -- CinCor Pharma, Inc. NASDAQ: CINC a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that its management team will present at the 32nd Annual Oppenheimer Healthcare Conference taking place March 15-17, 2022. 